Can I read COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study on EtoBox?

COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study by Lennard Y.W. Lee; Maria C. Ionescu; Thomas Starkey; Martin Little; Michael Tilby; Arvind R. Tripathy; Hayley S. Mckenzie; Youssra Al-Hajji; Nathan Appanna; Matthew Barnard; Liza Benny; Alexander Burnett; Emma L. Cattell; James J. Clark; Sam Khan; Qamar Ghafoor; Hari Panneerselvam; George Illsley; Catherine Harper-Wynne; Rosie J. Hattersley; Alvin JX. Lee; Oliver Lomas; Justin KH. Liu; Amanda McCauley; Matthew Pang; Jennifer S. Pascoe; James R. Platt; Grisma Patel; Vijay Patel; Vanessa A. Potter; Amelia Randle; Anne S. Rigg; Tim M. Robinson; Tom W. Roques; René L. Roux; Stefan Rozmanowski; Harriet Taylor; Mark H. Tuthill; Isabella Watts; Sarah Williams; Andrew Beggs; Tim Iveson; Siow M. Lee; Gary Middleton; Mark Middleton; Andrew Protheroe; Matthew W. Fittall; Tom Fowler; Peter Johnson; Emma Kinloch; Emily Lam; Gillian Murphy; Malcolm Rhodes; Kate Robinson; Sanskriti Swarup; Keeley Bernhardt; Jola Bytyci; Yuxin Ying; Sukhmunni Johal; Remarez Sheehan is a Medicine article available to read on EtoBox.

What is COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study about?

## Purpose: People living with cancer and haematological malignancies are at an increased risk of hospitalisation and death following infection with acute respiratory syndrome coronavirus 2. coronavirus third dose vaccine boosters are proposed to boost waning immune responses in immunocompromised individuals and increase coronavirus protection; however, their effectiveness has not yet been systematically evaluated. ## Methods: This study is a population-scale real-world evaluation of the united kingdom's third dose vaccine booster programme for cancer patients from 8th december 2020 to 7th december 2021. the cancer cohort comprises individuals from public health england's national cancer dataset, excluding individuals less than 18 years. a test-negative case-control design was used to assess the third dose booster vaccine effectiveness. multivariable logistic regression models were fitted to compare risk in the cancer cohort relative to the general population. ## Results: The cancer cohort comprised of 2,258,553 tests from 361,098 individuals. third dose boosters were evaluated by reference to 87,039,743 polymerase chain reaction coronavirus tests. vaccine effectiveness against bre

Who reads COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study?

Author

Lennard Y.W. Lee; Maria C. Ionescu; Thomas Starkey; Martin Little; Michael Tilby; Arvind R. Tripathy; Hayley S. Mckenzie; Youssra Al-Hajji; Nathan Appanna; Matthew Barnard; Liza Benny; Alexander Burnett; Emma L. Cattell; James J. Clark; Sam Khan; Qamar Ghafoor; Hari Panneerselvam; George Illsley; Catherine Harper-Wynne; Rosie J. Hattersley; Alvin JX. Lee; Oliver Lomas; Justin KH. Liu; Amanda McCauley; Matthew Pang; Jennifer S. Pascoe; James R. Platt; Grisma Patel; Vijay Patel; Vanessa A. Potter; Amelia Randle; Anne S. Rigg; Tim M. Robinson; Tom W. Roques; René L. Roux; Stefan Rozmanowski; Harriet Taylor; Mark H. Tuthill; Isabella Watts; Sarah Williams; Andrew Beggs; Tim Iveson; Siow M. Lee; Gary Middleton; Mark Middleton; Andrew Protheroe; Matthew W. Fittall; Tom Fowler; Peter Johnson; Emma Kinloch; Emily Lam; Gillian Murphy; Malcolm Rhodes; Kate Robinson; Sanskriti Swarup; Keeley Bernhardt; Jola Bytyci; Yuxin Ying; Sukhmunni Johal; Remarez Sheehan

Publisher

Elsevier BV

Published

2022

Language

EN

Field

Medicine (Health Sciences)